358 related articles for article (PubMed ID: 27706599)
1. MicroRNA-338-3p inhibits glucocorticoid-induced osteoclast formation through RANKL targeting.
Zhang XH; Geng GL; Su B; Liang CP; Wang F; Bao JC
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706599
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-17/20a inhibits glucocorticoid-induced osteoclast differentiation and function through targeting RANKL expression in osteoblast cells.
Shi C; Qi J; Huang P; Jiang M; Zhou Q; Zhou H; Kang H; Qian N; Yang Q; Guo L; Deng L
Bone; 2014 Nov; 68():67-75. PubMed ID: 25138550
[TBL] [Abstract][Full Text] [Related]
3. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
[TBL] [Abstract][Full Text] [Related]
4. Osteoclast signaling-targeting miR-146a-3p and miR-155-5p are downregulated in Paget's disease of bone.
Stephens E; Roy M; Bisson M; Nguyen HD; Scott MS; Boire G; Bouchard L; Roux S
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165852. PubMed ID: 32485219
[TBL] [Abstract][Full Text] [Related]
5. miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway.
Zhao C; Sun W; Zhang P; Ling S; Li Y; Zhao D; Peng J; Wang A; Li Q; Song J; Wang C; Xu X; Xu Z; Zhong G; Han B; Chang YZ; Li Y
RNA Biol; 2015; 12(3):343-53. PubMed ID: 25826666
[TBL] [Abstract][Full Text] [Related]
6. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
7. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
[TBL] [Abstract][Full Text] [Related]
8. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
[TBL] [Abstract][Full Text] [Related]
9. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
10. Estrogen inhibits osteoclasts formation and bone resorption via microRNA-27a targeting PPARγ and APC.
Guo L; Chen K; Yuan J; Huang P; Xu X; Li C; Qian N; Qi J; Shao Z; Deng L; He C; Xu J
J Cell Physiol; 2018 Jan; 234(1):581-594. PubMed ID: 30272823
[TBL] [Abstract][Full Text] [Related]
11. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
[TBL] [Abstract][Full Text] [Related]
12. Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption.
Mizoguchi F; Izu Y; Hayata T; Hemmi H; Nakashima K; Nakamura T; Kato S; Miyasaka N; Ezura Y; Noda M
J Cell Biochem; 2010 Apr; 109(5):866-75. PubMed ID: 20039311
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-29a represses osteoclast formation and protects against osteoporosis by regulating PCAF-mediated RANKL and CXCL12.
Lian WS; Ko JY; Chen YS; Ke HJ; Hsieh CK; Kuo CW; Wang SY; Huang BW; Tseng JG; Wang FS
Cell Death Dis; 2019 Sep; 10(10):705. PubMed ID: 31543513
[TBL] [Abstract][Full Text] [Related]
14. miR-31 controls osteoclast formation and bone resorption by targeting RhoA.
Mizoguchi F; Murakami Y; Saito T; Miyasaka N; Kohsaka H
Arthritis Res Ther; 2013; 15(5):R102. PubMed ID: 24004633
[TBL] [Abstract][Full Text] [Related]
15. Expression profiling of microRNAs in RAW264.7 cells treated with a combination of tumor necrosis factor alpha and RANKL during osteoclast differentiation.
Kagiya T; Nakamura S
J Periodontal Res; 2013 Jun; 48(3):373-85. PubMed ID: 23078176
[TBL] [Abstract][Full Text] [Related]
16. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
17. miR-145-5p Increases Osteoclast Numbers In Vitro and Aggravates Bone Erosion in Collagen-Induced Arthritis by Targeting Osteoprotegerin.
Chen Y; Wang X; Yang M; Ruan W; Wei W; Gu D; Wang J; Guo X; Guo L; Yuan Y
Med Sci Monit; 2018 Jul; 24():5292-5300. PubMed ID: 30059491
[TBL] [Abstract][Full Text] [Related]
18. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
[TBL] [Abstract][Full Text] [Related]
19. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
20. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis.
Hofkens W; Grevers LC; Walgreen B; de Vries TJ; Leenen PJ; Everts V; Storm G; van den Berg WB; van Lent PL
J Control Release; 2011 Jun; 152(3):363-9. PubMed ID: 21396411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
